Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428701 · ClinicalTrials.gov registry record · Phase 4
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
A Phase 4 study of Gastric Ulcer, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT00428701 is a Phase 4 study of Gastric Ulcer that has completed, run by AstraZeneca. The registered enrollment target is 40 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT00428701, a Phase 4 study of Gastric Ulcer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.
Conditions Studied
Interventions
- DRUG Esomeprazole Sodium
Study Locations (5)
Tennessee
- Research Site - Memphis
- Research Site - Nashville
Delaware
- Research SIte - Newark
Louisiana
- Research Site - Shreveport
Pennsylvania
- Research Site - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-10 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00428701
The ClinicalTrials.gov registry entry for NCT00428701 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastric Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Esomeprazole Sodium is the first listed.
NCT00428701 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Tennessee, Delaware, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00428701 about?
NCT00428701 is a clinical study titled "An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium". This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.
What is the current status of trial NCT00428701?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-10. Estimated completion is 2006-11.
What conditions does trial NCT00428701 study?
This clinical trial studies the following conditions: Gastric Ulcer.
What interventions are being tested in trial NCT00428701?
The interventions under investigation include: Esomeprazole Sodium (DRUG).
Who is sponsoring clinical trial NCT00428701?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00428701 being conducted?
This trial has 5 study locations across Delaware, Louisiana, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.